Related Experiment Videos
[Clinical study on norfloxacin in pediatrics]
M Minamitani1, K Hachimori, K Kaneda
1Department of Infectious Diseases, Tokyo Metropolitan, Komagome, Hospital.
The Japanese Journal of Antibiotics
|May 1, 1990
Summary
Norfloxacin (NFLX) effectively treated pediatric infections, achieving a 92.9% eradication rate against common bacterial pathogens like Salmonella and Campylobacter with no observed side effects.
Area of Science:
- Pharmacology
- Infectious Diseases
- Pediatrics
Context:
- Norfloxacin (NFLX), a pyridonecarboxylic acid antibiotic, was evaluated for pediatric use.
- Pediatric bacterial enteritis and dysentery are significant health concerns.
Purpose:
- To investigate the clinical efficacy and safety of norfloxacin in treating pediatric infections.
Summary:
- Thirteen pediatric patients with various bacterial infections (Campylobacter enteritis, Salmonella enteritis, dysentery, acute enteritis) received norfloxacin.
- Pathogen eradication was successful in 13 out of 14 identified strains (92.9% overall eradication rate).
- No adverse side effects or abnormal laboratory findings were reported during norfloxacin treatment.
Impact:
- Demonstrates the potential of norfloxacin as a safe and effective treatment option for specific pediatric bacterial infections.
- Provides evidence supporting the use of fluoroquinolones in pediatric infectious disease management.
- Highlights the need for continued research into antibiotic efficacy in pediatric populations.